Demogeot discusses his team's GETUG 14 findings regarding early administration of ADT plus high-dose radiotherapy for intermediate to high risk prostate cancer. Findings from GETUG 14 show short-term ...

"When we looked at the same phenotypic data, but focusing on each immunochemistry protein markers, we had 10 patients with AR negative tumor with clearly worse prognosis, and synaptophysin-positive ...

"At the University of Michigan, we've actually started to offer prostate MRI without contrast for patients on active surveillance, which has been a really exciting change," says Benjamin Pockros, MD, ...

“We are pleased that a first patient has been imaged in the CA-NINE trial, which supports potential label expansion for TLX250-CDx into recurrent, metastatic disease,” says David N. Cade. The first ...

"The radiologist more than ever has to be part of the care team," says Phillip H. Kuo, MD, PhD, FACR. In this interview, Phillip H. Kuo, MD, PhD, FACR, discusses the key elements of a PSMA-PET report ...

"I would say the take-home message is that we found that from a patient-centered orientation, telehealth for new and established patients have comparably high satisfaction scores but provide ...

"The addition of radium-223 to SABR metastasis-directed therapy in low-volume bone-metastatic hormone-sensitive prostate cancer does not delay progression of disease in the RAVENS study," said Ana ...

“The toxicity benefits of aggressive margin reduction persist beyond the acute phase post-SBRT," the authors wrote. Aggressive margin reduction with MRI-guided stereotactic body radiotherapy (SBRT) ...

In total, the phase 3 UTOPIA trial plans to enroll 87 patients with LG-IR-NMIBC to assess the safety and efficacy of UGN-103. The first patient has been dosed in the phase 3 UTOPIA trial (NCT06331299) ...

Enfortumab vedotin plus pembrolizumab was previously granted a priority review designation from the MHLW.